The Immunogenicity of CRISP1 Plasmid-Based Contraceptive Vaccine can be Improved When Using Chitosan Nanoparticles as the Carrier.

about

The Immunogenicity of CRISP1 Plasmid-Based Contraceptive Vaccine can be Improved When Using Chitosan Nanoparticles as the Carrier.

Item

http://www.wikidata.org/entity/Q50905925

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年学术文章

@wuu

2016年学术文章

@zh

2016年学术文章

@zh-cn

2016年学术文章

@zh-hans

2016年学术文章

@zh-my

2016年学术文章

@zh-sg

2016年學術文章

@yue

2016年學術文章

@zh-hant

name

The Immunogenicity of CRISP1 P ...... Nanoparticles as the Carrier.

@en

The Immunogenicity of CRISP1 P ...... Nanoparticles as the Carrier.

@nl

type

Item

label

The Immunogenicity of CRISP1 P ...... Nanoparticles as the Carrier.

@en

The Immunogenicity of CRISP1 P ...... Nanoparticles as the Carrier.

@nl

prefLabel

The Immunogenicity of CRISP1 P ...... Nanoparticles as the Carrier.

@en

The Immunogenicity of CRISP1 P ...... Nanoparticles as the Carrier.

@nl

P1476

The Immunogenicity of CRISP1 P ...... Nanoparticles as the Carrier.

@en

P2093

Jin Luo

http://www.w3.org/2001/XMLSchema#string

Jing Yang

http://www.w3.org/2001/XMLSchema#string

Wang-Ming Xu

http://www.w3.org/2001/XMLSchema#string

Xue-Li Liu

http://www.w3.org/2001/XMLSchema#string

Ya-Qin Wang

http://www.w3.org/2001/XMLSchema#string

Yi Zhang

http://www.w3.org/2001/XMLSchema#string

P2860

Characterization of a human glycoprotein with a potential role in sperm-egg fusion: cDNA cloning, immunohistochemical localization, and chromosomal assignment of the gene (AEGL1)

The human cysteine-rich secretory protein (CRISP) family. Primary structure and tissue distribution of CRISP-1, CRISP-2 and CRISP-3

Antisperm contraceptive vaccines: where we are and where we are going?

Characterization of immune response in mice to plasmid DNA encoding human sperm associated antigen 9 (SPAG9)

Construction of a catsper1 DNA vaccine and its antifertility effect on male mice.

Chitosan solution enhances both humoral and cell-mediated immune responses to subcutaneous vaccination.

Chitosan solution enhances the immunoadjuvant properties of GM-CSF.

Progress in developing cationic vectors for non-viral systemic gene therapy against cancer.

Advances in using chitosan-based nanoparticles for in vitro and in vivo drug and gene delivery.

Progesterone-loaded chitosan microspheres: a long acting biodegradable controlled delivery system.

P304

643-653

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/AJI.12513

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2016-04-22T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27105782

http://www.w3.org/2001/XMLSchema#string

P921

nanoparticle